Completed PHASE4 INTERVENTIONAL 1-arm NCT00571103

Acamprosate in the Treatment of Pathological Gambling

Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling

Sponsor: Forest Laboratories

Conditions Pathological Gambling

Interventions acamprosate

Updated 7 times since 2017 Last updated: Apr 24, 2017 Started: Oct 31, 2007 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00571103, this PHASE4 trial focuses on Pathological Gambling and remains completed. Sponsored by Forest Laboratories, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Jul 2017 [monthly]

Completed PHASE4

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
University of Iowa
University of Nebraska

Data source: University of Iowa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.